SOUTHWEST SOCIETY OF HEALTH SYSTEM PHARMACISTS Consultant CE Weekend 2014 Saturday and Sunday, September 20 th and 21 st, 2014 WellCare Health Plans Inc. Ren Center 8735 Henderson Road Tampa, FL 33634 Please R.S.V.P. before 5 PM on September 5th, 2014 to: www.fshp.org, Education Tab, Calendar of Events (SWSHP reserves the right to limit registration) NOTE the registration fees for this event are as follows: Southwest Society members: FREE. FSHP members (non SW Society): FREE Non member Pharmacists FSHP: $180.00 Non member Pharmacy Technicians: $50.00 Target Audience: Pharmacists and pharmacy technicians (regardless of practice setting) including Licensed Consultant Pharmacists. (T) indicates objectives that are applicable for technicians. We encourage participation in our programs by all qualified persons without regard to race, sex, creed, national origin or religion. Programming will provide an in depth representation with fair, full disclosures and equitable balance.
Schedule of Continuing Education Programs Saturday, September 20 th, 2014 7:00 a.m. 8:00 a.m. Registration TRACK 1: AMBULATORY CARE 8:00 a.m. 9:00 a.m. 1.0hr 0163 9999 14 216 L01 P/0163 9999 14 216 L01 T COPD Clinical Pearls Ryan Wargo, Pharm.D., BCACP Assistant Professor & Director of Admissions LECOM School of Pharmacy Bradenton Florida 1. Discuss new and emerging therapies for the management of COPD. (T) 2. Identify key areas for pharmacist involvement in COPD management. 3. Identify key monitoring parameters and medication related adverse effects associated with COPD management. (T) 9:00 a.m. 10:00 a.m. 1.0hr 0163 9999 14 217 L01 P/0163 9999 14 217 L01 T OverS.U.P.plying the ICU: Stress Ulcer Prophylaxis Joby Palathinkal, Pharm.D. Palms of Pasadena Hospital HCA Healthcare 1. Review the epidemiology/pathophysiology of stress ulcers. 2. Define acute risk factors for stress ulcers and when to initiate prophylaxis. (T) 3. Explain the pharmacological differences between current acid suppressive therapies on the market. 4. Describe the potential adverse effects of long term acid suppression. (T) 5. Evaluate clinical trials and suggest first line treatment recommendations. 10:00 a.m. 11:00 a.m. 1.0hr 0163 9999 14 218 L04 P/0163 9999 14 218 L04 T Emerging Innovations in Pharmacy Practice Kenneth Lanier, Pharm.D. Cofounder and President of Praetorian Rx LLC 1. Review the innovative process and explain how it can be applied to pharmacy. (T) 2. Identify the process of "Dispensing" a solution. (T) 3. Explain how to leverage innovation to improve patient outcomes and enhance your value as a pharmacist, technician or as a business. (T) 4. Describe how to use Medication Therapy Management to identify customized solutions that meet the patient s needs. (T) 5. Review how compounding can address unique therapy challenges. (T) 6. Obtain a functional understanding of how to use Osterwalder s business model canvas to develop programs in your pharmacy. (T) 11:00 a.m. 11:10 a.m. Break
TRACK 2: INFECTIOUS DISEASE AND IMMUNIZATIONS 11:10 a.m. 12:10 p.m. 1.0hr 0163 9999 14 219 L04 P/0163 9999 14 219 L04 T Microbiology 101: What You Wish You Had Learned in Pharmacy School Lindsey Childs Kean, Pharm.D., MPH, BCPS Clinical Assistant Professor University of Florida College of Pharmacy St. Pete Campus Department of Pharmacotherapy and Translational Research 1. Discuss susceptibility testing and how it impacts treatment. (T) 2. Compare and contrast the mechanisms of antimicrobial resistance. (T) 3. Explain the role of antibiograms in clinical practice. 4. Given a patient case, determine which antimicrobial agent(s) would be most effective for treatment. 12:10 p.m. to 1:10 p.m. Lunch 1:10 p.m. 2:10 p.m. 1.0hr 0163 9999 14 220 L01 P/0163 9999 14 220 L01 T Bad Bugs, New Drugs: New Antimicrobials for the Treatment of Gram Positive infections Jamie Kisgen, Pharm.D., BCPS Pharmacotherapy Specialist Infectious Diseases Sarasota Memorial Health Care System 1. Review the latest FDA incentives for antimicrobial development. (T) 2. Describe the newest antimicrobial agents for the treatment of gram positive bacteria. 3. Compare and contrast the pros and cons of Dalbavancin, Oritavancin, and Tedizolid. 4. Discuss the role of these new agents in the current treatment paradigm. (T) 2:10 p.m. 3:10 p.m. 1,0hr 0163 9999 14 221 L01 P/0163 9999 14 221 L01 T Immunization Update and Review for Florida Pharmacists Katherine Tromp, Pharm.D., Assistant Professor of Pharmacy Practice and Director of Distance Education LECOM School of Pharmacy Bradenton 1. Utilize the adult immunization schedules recommended by the Advisory Committee on Immunization Practices (ACIP)/CDC. 2. Differentiate amongst the different vaccines available for each indication. 3. Recognize the differences in immunization of special populations (neonates and infants, pregnancy, immunocompromised, transplant. (T) 4. Identify contraindications and precautions to immunizations. 5. Discuss general immunization adverse events. (T)
TRACK 3: GENERAL MEDICINE 3:10 p.m. 4:10 p.m. 1.0hr 0163 9999 14 222 L01 P/0163 9999 14 222 L01 T Management of Patients on Targeted Therapies: TKIs and VEGF Inhibitors Linda Linderbeck, BSPharm, BCOP General Medicine and Oncology Hematology Tampa General Hospital 1. Recognize risk of fatality in patients receiving tyrosine kinase inhibitor and VEGF inhibitor therapies. 2. Describe the class side effects of various targeted therapies. (T) 3. Discuss the high risk drug drug interactions with tyrosine kinase and VEGF inhibitors. (T) 4. Recommend monitoring and management strategies for patients on target therapies. 4:10 p.m. 4:20 p.m. Break 4:20 p.m. 5:20 p.m. 1.0hr 0163 9999 14 223 L04 P/0163 9999 14 223 L04 T A.S.P.E.N. Clinical Guidelines Update on Parenteral Nutrition Ordering, Order Review, Compounding, Labeling, and Dispensing Julianne Harcombe, BSPharm, BCNSP St. Joseph s Hospital 1. Acknowledge the A.S.P.E.N. Clinical Guidelines on Parenteral Nutrition (PN) Ordering, Order Review, Compounding, Labeling and Dispensing. (T) 2. Discuss the clinical advantages or disadvantages of commercially available premade multichambered PN formulations. 3. Describe the benefits of integrating nutrition in the Comprehensive Geriatric Assessment (CGA). (T) 5:20 p.m. 6:20 p.m. 1.0hr 0163 9999 14 224 L01 P/0163 9999 14 224 L01 T Type 2 Diabetes: Its Personal Rachel Franks, Pharm.D., BCACP, CDE Assistant Professor/ Ambulatory Care Department of Pharmacotherapeutics & Clinical Research University of South Florida College of Pharmacy 1. Select individualized glucose goals for patients with type 2 diabetes. 2. List advantages and disadvantages of various classes of medications used to treat type 2 diabetes. 3. Select ideal therapeutic agents using patient specific characteristics. 4. Explain what an A1c measures and how it relates to blood glucose. (T) 5. Recognize A1c and blood glucose values that are elevated for most patients. (T) 6. Recognize medications from various classes used to treat Type 2 Diabetes. (T) 6:20 p.m. Adjourn
Schedule of Continuing Education Programs Sunday, September 21 st, 2014 7:30 a.m. 8:00 a.m. Registration TRACK 3: MEDICATION ERRORS/NARCOTIC DIVERSION 8:00 a.m. 9:00 a.m. 1.0hr 0163 9999 14 225 L04 P/0163 9999 14 225 L04 T To Steal or Not to Steal: The Art of Managing Controlled Substances Nancy Elrod, Pharm.D., BCPS Director of Patient Safety HCA Corporation 1. Describe the effects of controlled substance diversion on patient safety. (T) 2. List at least 3 opportunities for diversion prevention. (T) 3. Identify various individuals who may contribute to active diversion prevention. (T) 4. Define key concepts in resolving a suspected diversion. (T) 9:00 a.m. 11:00 a.m. 2.0hrs 0163 9999 14 226 L05 P/0163 9999 14 226 L05 T Medication Error Prevention in the Pharmacy Environment Eric Renker, Pharm.D., CPh Director of Pharmacy Florida Hospital of Tampa 1. State the definitions of medication safety events. (T) 2. Discuss the impact of adverse drug events and medication errors. (T) 3. Describe high risk medications and safe medication practices. (T) 4. Explain the process for reporting an adverse drug event or medication error. (T) 5. Discuss the Root Cause Analysis process for reviewing medication errors. (T) 6. List four practices that can prevent medication errors and adverse events. (T) 11:00 a.m. Adjourn Maximum of 12 hours of General C.E. credits or 12 Consultant Recertification CE credits. Please return your Request for Continuing Education and Evaluation forms in to a SWSHP representative upon leaving the meeting. FSHP will upload credits into CE Broker. The Florida Society of Health System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been accredited for: 12 hours (1.2CEUs) Knowledge Based CPE The Florida Society of Health System Pharmacists Is approved by the Florida Board of Pharmacy as a provider of Consultant Re Certification, HIV and Medication Errors Credits.